GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Capex-to-Operating-Income

Evotec SE (WBO:EVT) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Evotec SE's Capital Expenditure for the three months ended in Dec. 2023 was €-66.04 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-11.67 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Evotec SE Capex-to-Operating-Income Historical Data

The historical data trend for Evotec SE's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Capex-to-Operating-Income Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 1.91 2.85 8.70 -

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.64 - - -

Competitive Comparison of Evotec SE's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Evotec SE's Capex-to-Operating-Income falls into.



Evotec SE Capex-to-Operating-Income Calculation

Evotec SE's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-215.998) / -42.497
=N/A

Evotec SE's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-66.042) / -11.668
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evotec SE  (WBO:EVT) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Evotec SE Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Evotec SE's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (WBO:EVT) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines